Delay in Capital Reduction Schedule Under Rehabilitation Plan, Pending Re-disclosure
- Capital reduction is a mandatory measure following approval of the rehabilitation plan on March 27, 2026, involving cancellation of 250,000 common shares held by a specific shareholder (Lee) without compensation
- Original cancellation date (April 29, 2026) has been delayed due to procedural issues; new share listing date also undetermined. Re-disclosure when schedule is confirmed
- Company plans to issue convertible bonds and corporate bonds in accordance with rehabilitation plan
- This filing is a correction of the material change report on capital reduction submitted on March 30, 2026
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: [Correction of Description] Report on Major Matters (Decision on Capital Reduction)
- Company: Dongsung Pharmaceutical (002210)
- Submission: Dongsung Pharmaceutical Co., Ltd.
- Receipt: 04-29-2026
- Amended (Refer to related filing)